Functional Diabetic Retinopathy: A Switch to Control Diabetes - Related Complications and Vision Loss
Bhim B Rai1,2*, Deepa Rai3 and Ted Maddess1
1John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia
2Ophthalmology Department, JDW National Referral Hospital, Thimphu, Bhutan
3Warrigal Aged Care Facility, Calwell, ACT, Australia
*Corresponding Author: Bhim B Rai, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.
Received:
February 27, 2023; Published: March 01, 2023
Burden of diabetes
The International Diabetes Federation estimated the global prevalence of DM at 463 million in 2019 [1]. Diabetic retinopathy (DR) is a major complication and a leading cause of visual loss [2]. Among diabetics, global prevalence for DR was 19–25%, 6% for vision-threatening DR (VTDR), and 4% for diabetic macular oedema (DMO) [3]. In 2020, the number of adults worldwide with DR, VTDR, and DMO was estimated to be 103.1 million, 28.5 million, and 18.8 million, respectively [3]. By 2045, it is projected that there will be 700 million people with DM, 160.5 million with DR, 44.8 million with VTDR, and 28.6 million with DMO [1,3].
Keywords: Diabetic Retinal Neurodegeneration; Diabetic Retinopathy; Functional Diabetic Retinopathy; Perimetry; Retinal Sensitivity; Structure-Function Correlation
References
- Saeedi P., et al. “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 (th) edition”. Diabetes Research and Clinical Practice 157 (2019): 107843.
- Wang W and Lo ACY. “Diabetic Retinopathy: Pathophysiology and Treatments”. International Journal of Molecular Sciences 6 (2018).
- Teo ZL., et al. “Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis”. Ophthalmology (2021).
- Lopes de Faria JM., et al. “Retinal nerve fibre layer loss in patients with type 1 diabetes mellitus without retinopathy”. British Journal of Ophthalmology 86 (2002): 725-728.
- van Dijk HW., et al. “Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes”. Investigative Ophthalmology and Visual Science 7 (2010): 3660-3665.
- Parravano M., et al. “Functional Retinal Impairment in Type 1 Diabetic Patients without any Signs of Retinopathy”. Ophthalmic Research 2 (2013): 108-112.
- Picconi F., et al. “Retinal neurodegeneration in patients with type 1 diabetes mellitus: the role of glycemic variability”. Acta Diabetology 5 (2017): 489-497.
- Simó R and Hernández C. “Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives”. Trends in Endocrinology and Metabolism 1 (2014): 23-33.
- Montesano G., et al. “Evidence for Structural and Functional Damage of the Inner Retina in Diabetes With No Diabetic Retinopathy”. Investigative Ophthalmology and Visual Science 3 (2021): 35.
- Rai BB., et al. “Comparing retinal thickness and Matrix 10-2 functional testing in diabetic macular edema”. Investigative Ophthalmology and Visual Science 7 (2020).
- Sabeti F., et al. “Multifocal pupillography identifies changes in visual sensitivity according to severity of diabetic retinopathy in type 2 diabetes”. Investigative Ophthalmology and Visual Science 8 (2015): 4504-4513.
- Rai BB., et al. “Comparing objective perimetry, matrix perimetry, and regional retinal thickness in mild diabetic macular edema”. Translational Vision Science and Technology 13 (2021): 32.
- Rai BB., et al. “Rapid objective testing of visual function matched to the ETDRS-grid, and its diagnostic power in AMD”. Ophthalmology Science 2 (2022): 1-9.
Citation
Copyright